vs

Side-by-side financial comparison of OCULAR THERAPEUTIX, INC (OCUL) and USCB FINANCIAL HOLDINGS, INC. (USCB). Click either name above to swap in a different company.

USCB FINANCIAL HOLDINGS, INC. is the larger business by last-quarter revenue ($22.2M vs $13.3M, roughly 1.7× OCULAR THERAPEUTIX, INC). USCB FINANCIAL HOLDINGS, INC. runs the higher net margin — 6.1% vs -488.0%, a 494.1% gap on every dollar of revenue. On growth, USCB FINANCIAL HOLDINGS, INC. posted the faster year-over-year revenue change (14.7% vs -22.4%). USCB FINANCIAL HOLDINGS, INC. produced more free cash flow last quarter ($42.5M vs $-57.1M). Over the past eight quarters, USCB FINANCIAL HOLDINGS, INC.'s revenue compounded faster (12.3% CAGR vs -5.3%).

Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.

USCB Financial Holdings, Inc. is a U.S.-headquartered bank holding company that offers comprehensive retail and commercial banking services, including deposit products, personal and business loans, wealth management, and digital banking tools. It primarily serves individual consumers, small and medium-sized enterprises, and local corporate clients across its operating regions in the United States, prioritizing personalized customer experiences and community-oriented financial services.

OCUL vs USCB — Head-to-Head

Bigger by revenue
USCB
USCB
1.7× larger
USCB
$22.2M
$13.3M
OCUL
Growing faster (revenue YoY)
USCB
USCB
+37.2% gap
USCB
14.7%
-22.4%
OCUL
Higher net margin
USCB
USCB
494.1% more per $
USCB
6.1%
-488.0%
OCUL
More free cash flow
USCB
USCB
$99.6M more FCF
USCB
$42.5M
$-57.1M
OCUL
Faster 2-yr revenue CAGR
USCB
USCB
Annualised
USCB
12.3%
-5.3%
OCUL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
OCUL
OCUL
USCB
USCB
Revenue
$13.3M
$22.2M
Net Profit
$-64.7M
$1.4M
Gross Margin
88.0%
Operating Margin
-526.5%
14.7%
Net Margin
-488.0%
6.1%
Revenue YoY
-22.4%
14.7%
Net Profit YoY
-33.6%
-80.3%
EPS (diluted)
$-0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OCUL
OCUL
USCB
USCB
Q4 25
$13.3M
$22.2M
Q3 25
$14.5M
$25.0M
Q2 25
$13.5M
$24.4M
Q1 25
$10.7M
$22.8M
Q4 24
$17.1M
$23.0M
Q3 24
$15.4M
$21.5M
Q2 24
$16.4M
$20.5M
Q1 24
$14.8M
$17.6M
Net Profit
OCUL
OCUL
USCB
USCB
Q4 25
$-64.7M
$1.4M
Q3 25
$-69.4M
$8.9M
Q2 25
$-67.8M
$8.1M
Q1 25
$-64.1M
$7.7M
Q4 24
$-48.4M
$6.9M
Q3 24
$-36.5M
$6.9M
Q2 24
$-43.8M
$6.2M
Q1 24
$-64.8M
$4.6M
Gross Margin
OCUL
OCUL
USCB
USCB
Q4 25
88.0%
Q3 25
87.8%
Q2 25
85.6%
Q1 25
88.2%
Q4 24
92.8%
Q3 24
89.9%
Q2 24
90.8%
Q1 24
91.0%
Operating Margin
OCUL
OCUL
USCB
USCB
Q4 25
-526.5%
14.7%
Q3 25
-472.3%
47.3%
Q2 25
-502.6%
44.0%
Q1 25
-597.5%
44.2%
Q4 24
-296.1%
39.6%
Q3 24
-298.2%
42.5%
Q2 24
-265.1%
39.8%
Q1 24
-214.0%
34.3%
Net Margin
OCUL
OCUL
USCB
USCB
Q4 25
-488.0%
6.1%
Q3 25
-477.3%
35.8%
Q2 25
-503.9%
33.4%
Q1 25
-598.7%
33.5%
Q4 24
-283.3%
30.0%
Q3 24
-236.6%
32.3%
Q2 24
-266.3%
30.3%
Q1 24
-438.9%
26.2%
EPS (diluted)
OCUL
OCUL
USCB
USCB
Q4 25
$-0.27
Q3 25
$-0.38
$0.45
Q2 25
$-0.39
Q1 25
$-0.38
Q4 24
$-0.25
Q3 24
$-0.22
$0.35
Q2 24
$-0.26
Q1 24
$-0.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OCUL
OCUL
USCB
USCB
Cash + ST InvestmentsLiquidity on hand
$737.1M
$38.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$654.3M
$217.2M
Total Assets
$808.1M
$2.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OCUL
OCUL
USCB
USCB
Q4 25
$737.1M
$38.5M
Q3 25
$344.8M
$56.8M
Q2 25
$391.1M
$54.8M
Q1 25
$349.7M
$98.0M
Q4 24
$392.1M
$77.0M
Q3 24
$427.2M
$38.5M
Q2 24
$459.7M
$77.3M
Q1 24
$482.9M
$126.5M
Stockholders' Equity
OCUL
OCUL
USCB
USCB
Q4 25
$654.3M
$217.2M
Q3 25
$258.2M
$209.1M
Q2 25
$305.9M
$231.6M
Q1 25
$265.9M
$225.1M
Q4 24
$315.3M
$215.4M
Q3 24
$352.0M
$213.9M
Q2 24
$377.7M
$201.0M
Q1 24
$408.0M
$195.0M
Total Assets
OCUL
OCUL
USCB
USCB
Q4 25
$808.1M
$2.8B
Q3 25
$410.9M
$2.8B
Q2 25
$451.3M
$2.7B
Q1 25
$405.9M
$2.7B
Q4 24
$457.9M
$2.6B
Q3 24
$490.4M
$2.5B
Q2 24
$517.1M
$2.5B
Q1 24
$538.9M
$2.5B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OCUL
OCUL
USCB
USCB
Operating Cash FlowLast quarter
$-54.2M
$42.8M
Free Cash FlowOCF − Capex
$-57.1M
$42.5M
FCF MarginFCF / Revenue
-430.9%
191.4%
Capex IntensityCapex / Revenue
21.4%
1.4%
Cash ConversionOCF / Net Profit
31.40×
TTM Free Cash FlowTrailing 4 quarters
$-216.9M
$95.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OCUL
OCUL
USCB
USCB
Q4 25
$-54.2M
$42.8M
Q3 25
$-50.7M
$20.1M
Q2 25
$-55.2M
$18.0M
Q1 25
$-44.7M
$14.6M
Q4 24
$-39.4M
$34.8M
Q3 24
$-36.6M
$11.3M
Q2 24
$-24.8M
$18.3M
Q1 24
$-33.9M
$8.1M
Free Cash Flow
OCUL
OCUL
USCB
USCB
Q4 25
$-57.1M
$42.5M
Q3 25
$-56.7M
$20.0M
Q2 25
$-56.5M
$18.0M
Q1 25
$-46.6M
$14.6M
Q4 24
$-39.6M
$34.5M
Q3 24
$-36.6M
$11.2M
Q2 24
$-25.5M
$18.2M
Q1 24
$-34.1M
$8.0M
FCF Margin
OCUL
OCUL
USCB
USCB
Q4 25
-430.9%
191.4%
Q3 25
-390.0%
80.3%
Q2 25
-419.7%
73.7%
Q1 25
-435.6%
63.9%
Q4 24
-232.0%
150.2%
Q3 24
-237.6%
52.2%
Q2 24
-155.4%
88.8%
Q1 24
-231.1%
45.4%
Capex Intensity
OCUL
OCUL
USCB
USCB
Q4 25
21.4%
1.4%
Q3 25
41.2%
0.5%
Q2 25
9.3%
0.2%
Q1 25
18.1%
0.2%
Q4 24
1.2%
1.4%
Q3 24
0.6%
0.4%
Q2 24
4.5%
0.4%
Q1 24
1.7%
0.5%
Cash Conversion
OCUL
OCUL
USCB
USCB
Q4 25
31.40×
Q3 25
2.25×
Q2 25
2.22×
Q1 25
1.91×
Q4 24
5.05×
Q3 24
1.63×
Q2 24
2.95×
Q1 24
1.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons